Skip to main content
. 2021 Feb;9(4):283. doi: 10.21037/atm-20-5360

Figure 4.

Figure 4

Kaplan-Meier survival curves. (A) OS in the TACE-apatinib group; (B) PFS in the TACE-apatinib group; (C) OS in the TACE-sorafenib group; (D) PFS in the TACE-sorafenib group. HR, hazard ratio; CI, confidence interval; OS, overall survival; TACE, transarterial chemoembolization; PFS, progression-free survival.